Hui-Di Lan

Hui-Di Lan

Auto-generated profile, based on publicly available information

Hui-Di Lan

School of Traditional Medicine, Guangxi University of Chinese Medicine, No. 13 Wu He Da Dao, Nanning, Guangxi 530000, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
SLShi-Bing Liang
Shi-Bing Liang
MFMin Fang
Min Fang
CLChang-Hao Liang
Chang-Hao Liang
HLHui-Di Lan
Hui-Di Lan
CSChen Shen
Chen Shen
JLJian-Ping Liu
Jian-Ping Liu
Chinese patent medicine (CPM) is an indispensable part of traditional Chinese medicine. Coronavirus Disease 2019 (COVID-19) manifests is an acute respiratory infectious disease. This systematic review aimed to evaluate the therapeutic effects and safety of oral CPM for COVID-19. We included randomized controlled trials (RCTs) that tested oral CPM for the treatment of COVID-19 identified from publications in CNKI, Wanfang, VIP, Web of Science, SinoMed, PubMed, Embase, BioRxiv, MedRxiv and arXiv before November 2nd, 2020. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool. Seven RCTs including 1079 participants were identified. The overall bias was assessed as “-high risk of bias” for all included trials. Oral CPM investigated were: Lianhua Qingwen capsule/granules (LHQW), Jinhua Qinggan granules (JHQG), Huoxiang Zhengqi dripping pills (HXZQ), Toujie Quwen granules (TJQW) and Lianhua Qingke granules (LHQK). Compared with conventional western therapy alone for people with COVID-19: regarding the main outcomes, the results showed that oral CPM combined with conventional western therapy improved cure rate (RR = 1.20, 95 % CI 1.04–1.38, involving LHQW and TJQW), reduced aggravation rate (RR = 0.50, 95 % CI 0.29 – 0.85, involving LHQW, JHQG, LHQK and TJQW); with regard to additional outcomes, the results showed that add-on oral CPM shortened the duration of fever, cough and fatigue, improved the recovery rate of cough and fatigue, and increased the improvement and recovery rate of chest CT manifestations. There were some differences in therapeutic effects among various CPMs for the same COVID-19 outcome. The use of TJQW and LHQG appeared not to increase the risk of adverse events, but JHQG may cause mild diarrhea. Low-certainty or very low-certainty evidence demonstrated that oral CPM may have add-on potential therapeutic effects for patients with non-serious COVID-19. These findings need to be further confirmed by well-designed clinical trials with adequate sample sizes.

19 October 2021 in Integrative Medicine Research
Verified
Journal Article
Open access
CLChun-Li Lu
Chun-Li Lu
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
XXXue Xue
Xue Xue
XZXiao-Wen Zhang
Xiao-Wen Zhang
XLXue-Han Liu
Xue-Han Liu
JLJian-Ping Liu
Jian-Ping Liu
We aimed to investigate use of infection control behaviours, preventative and therapeutic interventions, and outcomes among respondents to an online survey during the COVID-19 pandemic in China. The survey was designed by an international team, translated and adapted to simplified Chinese, including 132 kinds of traditional Chinese medicine (TCM) preparation recommended by guidelines. It was distributed and collected from February to May 2021, with data analysed by WPS spreadsheet and wjx.cn. Descriptive statistics were used to describe demographics and clinical characteristics, diagnosis, treatments, preventative behaviours and interventions, and their associated outcomes. The survey was accessed 503 times with 341 (67.8%) completions covering 23 provinces and four municipalities in China. Most (282/341, 82.7%) respondents reported no symptoms during the pandemic and the majority (290/341, 85.0%) reported having a SARS-CoV-2 PCR test at some point. Forty-five (13.2%) reported having a respiratory infection, among which 19 (42.2%) took one or more categories of modern medicine, e.g. painkillers, antibiotics; 16 (35.6%) used TCM interventions(s); while seven respondents combined TCM with modern medicine. All respondents reported using at least one behavioural or medical approach to prevention, with 22.3% taking TCM and 5.3% taking modern medicines. No respondents reported having a critical condition related to COVID-19. We found evidence of widespread use of infection control behaviours, modern medicines and TCM for treatment and prevention of COVID-19 and other respiratory symptoms. Larger scale studies are warranted, including a more representative sample exploring TCM preparations recommended in clinical guidelines.

18 February 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YJYue Jiang
Yue Jiang
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
ZYZe-Yu Yu
Ze-Yu Yu
XZXiao-Wen Zhang
Xiao-Wen Zhang
JLJing Li
Jing Li
JLJian-Ping Liu
Jian-Ping Liu
Background. Herpes zoster (HZ) is a common infection in individuals with acquired immunodeficiency syndrome (AIDS) patients. Traditional Chinese medicine (TCM) has been used widely in clinical practice for HZ, which remains not supportive of evidence. This review aimed to evaluate the effectiveness and safety of TCM in treating HIV-associated HZ. Methods. Nine electronic databases were searched for randomized controlled trials (RCTs) testing TCM in treating HIV-associated HZ. Data were extracted on citations, interventions, and outcomes, by two authors independently. For the quality evaluation, Cochrane risk-of-bias tool 2.0 was used. Meta-analyses were performed by Revman5.3 software. Effect estimation presented as risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data with their 95 confidence interval (CI). Results. Twelve RCTs (n=644) were included; the majority of them had a high or unclear risk of bias. Meta-analysis showed that pain intensity (VAS 05) in the Chinese herbal medicine (CHM) group was lower than it in the drugs group (MD=0.87, 95 CI [1.69, 0.04], two trials, n=93). Duration of herpes-related pain (days) of patients in the combination group was shorter than those in the drugs group (MD=9.19, 95 CI [16.73, 1.65], n=144). The incidence of postherpetic neuralgia (PHN) in the combination group was lower than in the drugs group (RR=0.49, 95 CI [0.25, 0.99], n=202). As for cure rate (complete absence of pain and herpes), two trials showed that CHM was better than drugs (RR=1.58, 95 CI [1.13, 2.22], n=93), five trials showed combination treatment was better than drugs (RR=1.40, 95 CI [1.08, 1.82], n=224). The cure rate in the acupuncture group was more than that in the drugs group (RR=1.99, 95 CI [1.18, 3.36], n=120). Four trials reported adverse effects and found no serious adverse events occurred. Conclusion. CHM and acupuncture demonstrate more benefits than drugs in pain relief, cure rate improvement, and incidence reduction of PHN. However, given the data limitation and TCM therapies diversity, the conclusions need to be verified in future trials.